Your browser doesn't support javascript.
loading
Treatment Resistance: A Time-Based Approach for Early Identification in First Episode Psychosis.
Dempster, Kara; Li, Annie; Sabesan, Priyadharshini; Norman, Ross; Palaniyappan, Lena.
Afiliação
  • Dempster K; Department of Psychiatry, Dalhousie University, Halifax, NS B3H 2E2, Canada.
  • Li A; Department of Anaesthesia, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5B7, Canada.
  • Sabesan P; Department of Psychiatry, Western University, London, ON N6A 5B7, Canada.
  • Norman R; Department of Psychiatry, Western University, London, ON N6A 5B7, Canada.
  • Palaniyappan L; Lawson Health Research Institute, London, ON N6C 2R5, Canada.
J Pers Med ; 11(8)2021 Jul 24.
Article em En | MEDLINE | ID: mdl-34442355
ABSTRACT
Although approximately 1/3 of individuals with schizophrenia are Treatment Resistant (TR), identifying these subjects prospectively remains challenging. The Treatment Response and Resistance in Psychosis working group defines <20% improvement as an indicator of TR, though its utility in First Episode Schizophrenia (FES) remains unknown. In a prospective cohort of FES (n = 129) followed up for 5 years, we evaluated two improvement thresholds for 'probable TR'; <20% and <50% based on positive, negative, and total symptoms. We ascertained (1) the ecological validity (i.e., the ability to identify an expected subgroup of 1/3rd of patients); (2) the predictive validity (i.e., ability to predict poor global functioning) and (3) the clinical utility (association with clozapine use at the 5th year). Using the criteria of a total symptom reduction of <50% or negative symptom reduction of <20% resulted in 'probable TR' rates of 37% and 33%, respectively. Using <20% positive or total symptoms criteria resulted in very low rates, indicating minimal utility in FES. <50% total symptom criterion best predicted the global functioning over 5 years. Clozapine use was only predicted by positive symptom criterion. Prospective characterization of TRS is possible at 6 months after FES through a time-based approach using a 50% threshold for symptom change in treatment-adherent patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article